<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>One of the most serious complications faced by patients with <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e> (IBD) is the potential development of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>There is a compelling need to enhance the accuracy of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> screening of IBD patients </plain></SENT>
<SENT sid="2" pm="."><plain>MicroRNAs (miRNAs) are small nonprotein-coding <z:chebi fb="40" ids="33697">RNAs</z:chebi> that play important roles in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> <z:e sem="disease" ids="C1326912" disease_type="Neoplastic Process" abbrv="">oncogenesis</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>In this study, we report differential miRNA expression in IBD patients with associated <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> from non-neoplastic tissue to <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and eventually <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>In addition, we identify and examine the role of dysregulated miRNAs in the TP53 pathway </plain></SENT>
<SENT sid="5" pm="."><plain>In our CD patients, six miRNAs were upregulated from non-neoplastic tissue to <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, but downregulated from <z:mpath ids='MPATH_589'>dysplasia</z:mpath> to <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> (miR-122, miR-181a, miR-146b-5p, let-7e, miR-17, miR-143) (P &lt; 0.001) </plain></SENT>
<SENT sid="6" pm="."><plain>Six differentially expressed miRNAs affected the TP53 pathway (miR-122, miR-214, miR-372, miR-15b, let-7e, miR-17) (P &lt; 0.001) </plain></SENT>
<SENT sid="7" pm="."><plain>Using two human <z:hpo ids='HP_0003003'>colon cancer</z:hpo> cell lines (HT-29 and HCT-116), E2F1, an upstream regulator of TP53, was downregulated in both cell lines transfected with let-7e (P &lt; 0.05) as well as in HCT-116 cells transfected with miR-17 (P &lt; 0.05) </plain></SENT>
<SENT sid="8" pm="."><plain>Additionally, cyclin G, a cell-cycle regulator miR-122 target was downregulated in both cell lines (P &lt; 0.05) </plain></SENT>
<SENT sid="9" pm="."><plain>Unique differentially expressed miRNAs were observed in CD-associated <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> progression </plain></SENT>
<SENT sid="10" pm="."><plain>Six of these miRNAs had a tumorigenic effect on the TP53 pathway; the effect of three of which was studied using cell lines </plain></SENT>
</text></document>